Roivant

Roivant Sciences Ltd. is a biopharmaceutical company based in Basel, Switzerland, founded in 2014 by Vivek Ramaswamy. The company focuses on accelerating the development and commercialization of innovative medicines through its unique "Vant" model, which involves creating specialized subsidiary companies that target specific therapeutic areas. This approach allows Roivant to efficiently license underutilized pharmaceutical assets and streamline operations. Roivant has successfully built over 20 subsidiaries, known as Vants, and has advanced more than 40 medicines into development. The company has achieved significant milestones, including 12 positive Phase 3 trials since 2019 and five FDA approvals. Its first commercial product, VTAMA® (tapinarof) cream, was launched in 2022 for the treatment of plaque psoriasis. Roivant's diverse pipeline includes therapies for various conditions, such as autoimmune diseases, neurological disorders, and rare diseases, showcasing its commitment to addressing unmet medical needs.